Meritage Portfolio Management Supernus Pharmaceuticals, Inc. Transaction History
Meritage Portfolio Management
- $1.63 Billion
- Q3 2024
A detailed history of Meritage Portfolio Management transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Meritage Portfolio Management holds 44,295 shares of SUPN stock, worth $1.58 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
44,295
Previous 39,967
10.83%
Holding current value
$1.58 Million
Previous $1.07 Million
29.19%
% of portfolio
0.08%
Previous 0.07%
Shares
15 transactions
Others Institutions Holding SUPN
# of Institutions
281Shares Held
60.6MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$370 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$218 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$181 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$103 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$93.7 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.9B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...